Millipore Sigma Vibrant Logo

676489 VEGFR2 Kinase Inhibitor IV - CAS 216661-57-3 - Calbiochem

The VEGFR2 Kinase Inhibitor IV, also referenced under CAS 216661-57-3, controls the biological activity of VEGFR2 Kinase. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.

Ficha de datos de seguridad (MSDS o SDS), certificado de análisis y de calidad (CoA y CoQ), expedientes, folletos y otros documentos disponibles.

Sinónimos: KDR/Flk-1 Kinase Inhibitor IV, 3-(3-Thienyl)-6-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidine, Vascular Endothelial Growth FactorReceptor 2 Kinase Inhibitor IV, VEGFR Tyrosine Kinase Inhibitor XVIII, VEGFR1 Kinase Inhibitor II, VEGFR3 Kinase Inhibitor II, PDGFR Tyrosine Kinase Inhibitor IX

Primary Target: VEGFR-2 KDR/Flk-1
676489
  
Recuperando precio...
No pudo obtenerse el precio
La cantidad mínima tiene que ser múltiplo de
Maximum Quantity is
Al finalizar el pedido Más información
Ahorró ()
 
—
Solicitar precio
—
Disponibilidad a confirmar Disponibilidad a confirmar
Ingrese cantidad 
Suspendido
Cantidades limitadas disponibles
Debe confirmarse disponibilidad
    El resto: se avisará
      El resto: se avisará
      Se avisará
      Póngase en contacto con el Servicio de Atención al Cliente
      Contact Customer Service

       

      Póngase en contacto con el Servicio de Atención al Cliente

      Descripción

      Replacement Information

      Tabla espec. clave

      CAS #Empirical Formula
      216661-57-3C₁₇H₁₃N₃OS
      Description
      Overview

      This product has been discontinued.





      A 3,6-diaryl substituted pyrazolopyrimidine that acts as a potent, reversible, and ATP-competitive inhibitor of VEGFR-2 (KDR/Flk-1; IC50 = 19 nM). Displays ~2-fold greater selectivity for VEGFR-2 over PDGFRβ (IC50 = 34 nM) and 10-fold greater selectivity over VEGFR-1 (Flt-1) and VEGFR-3 (Flt-4; IC50 = 190 nM) tyrosine kinase activity. Does not inhibit FGFR-1 or Src kinase activity (IC50 > 1.9 µM). Shown to inhibit VEGF-stimulated mitogenesis in human umbilical vein endothelial cells (IC50 = 387 nM). Inhibits Flt3 phosphorylation in Flt3/Itd-BaF3 cells.
      Catalogue Number676489
      Brand Family Calbiochem®
      SynonymsKDR/Flk-1 Kinase Inhibitor IV, 3-(3-Thienyl)-6-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidine, Vascular Endothelial Growth FactorReceptor 2 Kinase Inhibitor IV, VEGFR Tyrosine Kinase Inhibitor XVIII, VEGFR1 Kinase Inhibitor II, VEGFR3 Kinase Inhibitor II, PDGFR Tyrosine Kinase Inhibitor IX
      References
      ReferencesCools, J., et al. 2004. Cancer Res. 64, 6385.
      Fraley, M.E., et al. 2002. Bioorg. Med. Chem. Lett. 12, 2767.
      Product Information
      CAS number216661-57-3
      ATP CompetitiveY
      FormYellow solid
      Hill FormulaC₁₇H₁₃N₃OS
      Chemical formulaC₁₇H₁₃N₃OS
      ReversibleY
      Structure formula ImageStructure formula Image
      Applications
      Biological Information
      Primary TargetVEGFR-2 KDR/Flk-1
      Primary Target IC<sub>50</sub>19 nM
      Purity≥95% by HPLC
      Physicochemical Information
      Cell permeableN
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Número de referencia GTIN
      676489 0

      Documentation

      VEGFR2 Kinase Inhibitor IV - CAS 216661-57-3 - Calbiochem Ficha datos de seguridad (MSDS)

      Título

      Ficha técnica de seguridad del material (MSDS) 

      VEGFR2 Kinase Inhibitor IV - CAS 216661-57-3 - Calbiochem Certificados de análisis

      CargoNúmero de lote
      676489

      Referencias bibliográficas

      Visión general referencias
      Cools, J., et al. 2004. Cancer Res. 64, 6385.
      Fraley, M.E., et al. 2002. Bioorg. Med. Chem. Lett. 12, 2767.
      Ficha técnica

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision13-January-2010 RFH
      SynonymsKDR/Flk-1 Kinase Inhibitor IV, 3-(3-Thienyl)-6-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidine, Vascular Endothelial Growth FactorReceptor 2 Kinase Inhibitor IV, VEGFR Tyrosine Kinase Inhibitor XVIII, VEGFR1 Kinase Inhibitor II, VEGFR3 Kinase Inhibitor II, PDGFR Tyrosine Kinase Inhibitor IX
      DescriptionA 3,6-diaryl substituted pyrazolopyrimidine that acts as a potent, reversible, and ATP-competitive inhibitor of vascular endothelial cell growth factor receptor-2 (VEGFR-2; KDR/Flk-1) (IC50 = 19 nM). Displays ~2-fold greater selectivity for VEGFR-2 compared to platelet derived growth factor receptor β (PDGFRβ) and 10-fold selectivity compared to VEGFR-1 (Flt-1) and VEGFR-3 (Flt-4). Does not inhibit FGFR-1 or Src kinase activity. Reported to inhibit VEGF-stimulated mitogenesis in human umbilical vein endothelial cells (IC50 = 387 nM). Inhibits Flt3 phosphorylation in Flt3/Itd-BaF3 cells.
      FormYellow solid
      Intert gas (Yes/No) Packaged under inert gas
      CAS number216661-57-3
      Chemical formulaC₁₇H₁₃N₃OS
      Structure formulaStructure formula
      Purity≥95% by HPLC
      SolubilityDMSO (5 mg/ml)
      Storage Protect from light
      +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Standard Handling
      ReferencesCools, J., et al. 2004. Cancer Res. 64, 6385.
      Fraley, M.E., et al. 2002. Bioorg. Med. Chem. Lett. 12, 2767.